Related Experiment Video
Updated: Jan 21, 2026

Rapid and Low-cost Prototyping of Medical Devices Using 3D Printed Molds for Liquid Injection Molding
Published on: June 27, 2014
Dalbavancin use in an academic medical centre and associated cost savings
Amber C Streifel1, Monica K Sikka2, Christina D Bowen1
1Department of Pharmacy Services, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA.
Abstract:
Dalbavancin is a lipoglycopeptide antibiotic with unique weekly dosing active against Gram-positive organisms. This retrospective study included 37 patients receiving a mean of 2.7 weeks of dalbavancin. Nine patients (24%) were re-admitted to the hospital within 30 days. A total of 617 hospital days were saved, estimated to result in US$1 495 336 in savings and a mean cost avoidance of US$40 414 per patient. Dalbavancin provides a valuable antibiotic option that may minimise healthcare expenditure.
More Related Videos
11:28A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically
Published on: September 9, 2015
06:59A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
Published on: November 9, 2016
Related Concept Videos
Inhaled Medications
Heart Failure V: Medical Management
Endocarditis III: Medical Management
Myocarditis III: Medical Management
Pericarditis III: Medical Management
Nephrotic Syndrome II : Assessment and Medical Management